Top

Published in:

01-03-2008

Chemotherapy and the tumor microenvironment: the contribution of circulating endothelial cells

Author: Francesco Bertolini

Published in: Cancer and Metastasis Reviews | Issue 1/2008

Abstract

Anti-angiogenic drugs, alone or in combination with chemotherapeutics, are increasingly used by medical oncologists. In many cases, however, their mechanism of action and the tailoring of optimal dosage/schedule are still elusive. Circulating endothelial cell (CEC) and progenitor (CEP) number and viability are modulated in a large series of diseases including cancer, and look promising as surrogate biomarkers for the definition of the optimal biological dose of anti-angiogenic drugs and for patients’ stratification. Along with CECs and CEPs, potential EC- and CEP-related surrogate molecular markers such as VE-Cadherin and CD133 are currently under preclinical and clinical investigation.

Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. Cell, 100, 57–70.PubMedCrossRef

Folkman, J. (2007). Angiogenesis: An organizing principle for drug discovery? Naturalist Review Drug Discovery, 6, 273–286.CrossRef

Conway, E. M., Collen, D., & Carmeliet, P. (2001). Molecular mechanisms of blood vessel growth. Cardiovascular Research, 49, 507–521.PubMedCrossRef

Hladovec, J., & Rossamn, P. (1973). Circulating endothelial cells isolated together with platelets and the experimental modification of their counts in rats. Thrombosis Research, 3, 665–674.CrossRef

Lin, Y., Weisdorf, D. J., Solovey, A., & Hebbel, R. P. (2000). Origins of circulating endothelial cells and endothelial outgrowth from blood. Journal of Clinical Investigation, 105, 71–77.PubMed

Asahara, T., et al. (1997). Isolation of putative progenitor endothelial cells for angiogenesis. Science, 275, 964–967.PubMedCrossRef

Shi, Q., et al. (1998). Evidence for circulating bone marrow-derived endothelial cells. Blood, 92, 362–367.PubMed

Dignat-George, F., & Sampol, J. (2000). Circulating endothelial cells in vascular disorders: New insights into an old concept. European Journal of Haematology, 65, 215–220.PubMedCrossRef

Bertolini, F., et al. (2006). The multifaceted circulating endothelial cell in cancer: Towards marker and target identification. Nature Reviews Cancer, 6, 835–845.PubMedCrossRef

10.

Blann, A. D., et al. (2005). Circulating endothelial cells. Biomarker of vascular disease. Thrombosis and Haemostasis, 93, 228–235.PubMed

11.

Rafii, S., et al. (2002). Vascular and haematopoietic stem cells: Novel targets for anti-angiogenesis therapy? Nature Reviews Cancer, 2, 826–835.PubMedCrossRef

12.

Melero-Martin, J. M., et al. (2007). In vivo vasculogenic potential of human blood-derived endothelial progenitor cells. Blood, 109, 4761–4768.PubMedCrossRef

13.

Nagano, M., et al. (2007). Identification of functional endothelial progenitor cells suitable for the treatment of ischemic tissue using umbilical cord blood. Blood, 110, 151–160.PubMedCrossRef

14.

Yoder, M. C., et al. (2007). Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood, 109, 1801–1809.PubMedCrossRef

15.

Lyden, D., et al. (2001). Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nature Medicine, 7, 1194–1201.CrossRef

16.

De Palma, M., et al. (2003). Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nature Medicine, 9, 789–795.CrossRef

17.

Gothert, J. R., et al. (2004). Genetically tagging endothelial cells in vivo: Bone marrow-derived cells do not contribute to tumor endothelium. Blood, 104, 1769–1777.PubMedCrossRef

18.

Duda, D. G., et al. (2006). Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors. Blood, 107, 2774–2776.PubMedCrossRef

19.

Monsky, W. L., et al. (2002). Role of host microenvironment in angiogenesis and microvascular functions in human breast cancer xenografts: Mammary fat pad versus cranial tumors. Clinical Cancer Research, 8, 1008–1013.

20.

Peters, B. A., et al. (2005). Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nature Medicine, 11, 261–262.CrossRef

21.

Spring, H., et al. (2005). Chemokines direct endothelial progenitors into tumor neovessels. Proceedings of the National Academy of Sciences of the United States of America, 102, 18111–18116.PubMedCrossRef

22.

Ruzinova, M. B., et al. (2003). Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell, 4, 277–289.PubMedCrossRef

23.

Shaked, Y., et al. (2006). Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science, 313, 1785–1787.PubMedCrossRef

24.

Bertolini, F., et al. (2003). Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Research, 63, 4342–4346.PubMed

25.

Furstenberger, G., et al. (2006). Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. British Journal of Cancer, 94, 524–531.PubMedCrossRef

26.

Kerbel, R. S. (2006). Antiangiogenic therapy: A universal chemosensitization strategy for cancer? Science, 312, 1171–1175.PubMedCrossRef

27.

Conejo-Garcia, J. R., et al. (2004). Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of VEGF-A. Nature Medicine, 10, 950–958.CrossRef

28.

Grunewald, M., et al. (2006). VEGF-induced adult neovascularization: Recruitment, retention, and role of accessory cells. Cells, 124, 175–189.CrossRef

29.

De Palma, M., et al. (2005). Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cells, 8, 211–226.CrossRef

30.

Udagawa, T., et al. (2006). Analysis of tumor-associated stromal cells using SCID GFP transgenic mice: Contribution of local and bone marrow-derived host cells. FASEB Journal, 20, 95–102.PubMedCrossRef

31.

Kaplan, R. N., et al. (2005). VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature, 438, 820–827.PubMedCrossRef

32.

Hlatky, L., et al. (2002). Clinical application of antiangiogenic therapy: Microvessel density, what it does and doesn’t tell us. Journal of the National Cancer Institute, 94, 883–893.PubMed

33.

Jain, R. K. (2002). Tumor angiogenesis and accessibility: Role of vascular endothelial growth factor. Seminars in Oncology, 29(6 Suppl 16), 3–9.PubMed

34.

Motzer, R. J., et al. (2006). Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology, 24, 16–24.PubMedCrossRef

35.

Morgan, B., et al. (2003). Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: Results from two phase I studies. Journal of Clinical Oncology, 2, 3955–3964.CrossRef

36.

Shaked, Y., et al. (2005). Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cells, 7, 101–111.

37.

Mancuso, P., et al. (2001). Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood, 97, 3658–3661.PubMedCrossRef

38.

Zhang, H., et al. (2005). Circulating endothelial progenitor cells in multiple myeloma: Implications and significance. Blood, 105, 3286–3294.PubMedCrossRef

39.

Mancuso, P., et al. (2006). Circulating endothelial cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood, 108, 452–459.PubMedCrossRef

40.

Norden-Zfoni, A., et al. (2007). Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clinical Cancer Research, 13, 2643–2650.PubMedCrossRef

41.

Monestiroli, S., et al. (2001). Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Research, 61, 4341–4344.PubMed

42.

Jain, R. K. (2003). Molecular regulation of vessel maturation. Natural Medicines, 9, 685–693.CrossRef

43.

Batchelor, T. T., et al. (2007). AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cells, 11, 83–95.CrossRef

44.

Kerbel, R. S., & Kamen, B. A. (2004). The anti-angiogenic basis of metronomic chemotherapy. Nature Reviews Cancer, 4, 423–436.PubMedCrossRef

45.

Seaman, S., et al. (2007). Genes that distinguish physiological and pathological angiogenesis. Cancer Cells, 11, 539–554.CrossRef

46.

Smirnov, D. A., et al. (2006). Global gene expression profiling of circulating endothelial cells in patients with metastatic carcinomas. Cancer Research, 66, 2918–2922.PubMedCrossRef

47.

van Beijnum, J. R., et al. (2006). Gene expression of tumor angiogenesis dissected: Specific targeting of colon cancer angiogenic vasculature. Blood, 108, 2339–2348.PubMedCrossRef

48.

Kim, I., et al. (2005). CD144 (VE-cadherin). is transiently expressed by fetal liver hematopoietic stem cells. Blood, 106, 903–905.PubMedCrossRef

49.

Wang, L., O’Leary, H., Fortney, J., & Gibson, L. F. (2007). Ph+/VE-cadherin+ identifies a stem-cell like population of acute lymphoblastic leukemia sustained by bone marrow niche cells. Blood, prepublished online 16 July 2007. DOI 10.1182/blood-2007-01-068122.

50.

Rabascio, C., et al. (2004). Assessing tumor angiogenesis: Increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells. Cancer Research, 64, 4373–4377.PubMedCrossRef

51.

Lin, E. H., et al. (2007). Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence. Cancer, (Epub ahead of print, Jun 26, 2007).

52.

Yu, D., et al. (2007). Identification and clinical significance of mobilized endothelial progenitor cells in tumor vasculogenesis of hepatocellular carcinoma. Clinical Cancer Research, 13, 3814–3824.PubMedCrossRef

53.

Mehra, N., et al. (2006). Progenitor marker CD133 mRNA is elevated in peripheral blood of cancer patients with bone metastases. Clinical Cancer Research, 12, 4859–4866.PubMedCrossRef

54.

Ayers, M., Fargnoli, J., Lewin, A., Wu, Q., & Platero, J. S. (2007). Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist. Cancer Research, 67, 6899–6906.PubMedCrossRef

55.

Kerbel, R. S. (1991). Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. BioEssays, 13, 31–36.PubMedCrossRef

56.

Hida, K., et al. (2004). Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Research, 64, 8249–8255.PubMedCrossRef

57.

Streubel, B., et al. (2004). Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. New England Journal of Medicine, 351, 250–259.PubMedCrossRef

58.

Rigolin, G. M., et al. (2006). Neoplastic circulating endothelial cells in multiple myeloma with 13 q14 deletion. Blood, 107, 2531–2535.PubMedCrossRef

59.

Rigolin, G. M., et al. (2007). Neoplastic circulating endothelial-like cells in patients with acute myeloid leukaemia. European Journal of Haematology, 78, 365–373.PubMedCrossRef

60.

Bergsmedh, A., et al. (2001). Horizontal transfer of oncogenes by uptake of apoptotic bodies. Proceedings of the National Academy of Sciences of the United States of America, 98, 6407–6411.PubMedCrossRef

61.

Mortensen, K., Lichtenberg, J., Thomsen, P. D., & Larsson, L. I. (2004). Spontaneous fusion between cancer cells and endothelial cells. Cellular and Molecular Life Sciences, 61, 2125–2131.PubMedCrossRef

62.

van Heeckeren, W. J., Ortiz, J., Cooney, M. M., & Remick, S. C. (2007). Hypertension, proteinuria, and antagonism of VEGF signalling: Clinical toxicity, therapeutic target, or novel biomarker? Journal of Clinical Oncology, 25, 2993–2995.PubMedCrossRef

Title: Chemotherapy and the tumor microenvironment: the contribution of circulating endothelial cells
Author: Francesco Bertolini
Publication date: 01-03-2008
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 1/2008
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-007-9110-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2008

Osteopontin: regulation in tumor metastasis

The selectin–selectin ligand axis in tumor progression

Immune cells as mediators of solid tumor metastasis

Metastasis signatures: genes regulating tumor–microenvironment interactions predict metastatic behavior

The bone microenvironment in metastasis; what is special about bone?

The Met tyrosine kinase receptor in development and cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer